Gemini Therapeutics Inc. (GMTX)
NASDAQ: GMTX
· Real-Time Price · USD
1.35
0.00 (0.00%)
At close: Dec 30, 2022, 5:00 AM
Company Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD).
Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
The company also develops GEM307 for treatment of systemic diseases.
Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Gemini Therapeutics Inc.
| Country | United States |
| IPO Date | Aug 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | n/a |
Contact Details
Address: 300 One Kendall Square Cambridge, Massachusetts United States | |
| Website | https://www.geminitherapeutics.com |
Stock Details
| Ticker Symbol | GMTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001816736 |
| CUSIP Number | 36870G105 |
| ISIN Number | US36870G1058 |
| Employer ID | 85-1613057 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Georges Gemayel C.F.A., Ph.D. | Interim Pres & Chief Executive Officer and Executive Chairperson |
| Brian Piekos | Chief Bus. Officer, Chief Financial Officer, Principal Accounting & Principal Financial Officer |
| Jason Patrick Meyenburg M.B.A., M.D. | Advisor |
| Patrick Truesdell | Vice President of Fin. & Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 08, 2025 | 4 | Filing |
| Mar 26, 2025 | 4 | Filing |
| Mar 26, 2025 | 4 | Filing |
| Mar 21, 2025 | 4 | Filing |
| Mar 21, 2025 | 4 | Filing |
| Mar 12, 2025 | 4 | Filing |
| Mar 12, 2025 | 4 | Filing |
| Mar 12, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 03, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Feb 27, 2025 | S-8 | Filing |